Suchergebnisse - "Podzamczer, Daniel"

PubPharm (23)

1

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection : week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

enthalten in: The lancet. HIV | 2020

von Orkin, C. | DeJesus, E. | Sax, P. | +20

CommentIn: Lancet HIV. 2020 Jun;7(6):e374-e375. - PMID 32504568

2

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1 : 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

enthalten in: The lancet. HIV | 2018

von Molina, J. | Ward, D. | Brar, I. | +12

CommentIn: Lancet HIV. 2018 Jul;5(7):e336-e337. - PMID 29925488

3

Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults : a randomised, double-blind, active-controlled, non-inferiority phase 3 trial

enthalten in: The lancet. HIV | 2018

von Winston, A. | Post, F. | DeJesus, E. | +14

CommentIn: Lancet HIV. 2018 Apr;5(4):e156-e157. - PMID 29475803

4

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489) : a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

enthalten in: Lancet (London, England) | 2017

von Gallant, J. | Lazzarin, A. | Mills, A. | +14

5

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2) : 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

enthalten in: Lancet (London, England) | 2017

von Margolis, D. | Gonzalez-Garcia, J. | Stellbrink, H. | +21

6

Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r : OLE-MET substudy

enthalten in: HIV clinical trials | 2017

von Saumoy, M. | Tiraboschi, J. | Ordoñez-Llanos, J. | +6

7

Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients

enthalten in: The Journal of antimicrobial chemotherapy | 2016

von Curran, A. | Rojas, J. | Cabello, A. | +10

8

HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen

enthalten in: The Journal of infectious diseases | 2016

von Imaz, A. | Martinez-Picado, J. | Niubó, J. | +9

CommentIn: J Infect Dis. 2016 Nov 15;214(10):1473-1474. - PMID 27578846

9

Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients : 48 Week Results of the SIMRIKI Retrospective Study

enthalten in: PloS one | 2016

von Troya, J. | Ryan, P. | Ribera, E. | +19

ErratumIn: PLoS One. 2017 Feb 9;12 (2):e0172184. - PMID 28182783

10

Brief Report : Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2015

von Walmsley, S. | Baumgarten, A. | Berenguer, J. | +12

ErratumIn: J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):e33